Antigen-based testing but not real-time PCR correlates with SARS-CoV-2 virus culture

Andrew Pekosz, PhD,^{1, 2} Charles K. Cooper, MD,³ Valentin Parvu, PhD,³ Maggie Li, MS,¹ Jeffrey C. Andrews, MD,³ Yukari C. Manabe, MD,^{1, 4} Salma Kodsi, MS,³ Jeffry Leitch, PhD,³ Devin S. Garv. PhD.³ Celine Roger-Dalbert, MS³

#To whom correspondence should be addressed:

Andrew Pekosz, PhD 615 N. Wolfe Street Room W2116 Baltimore, Maryland 21205

Phone: 410-502-9306 Email: apekosz1@jhu.edu

Charles K. Cooper, MD Vice President of Medical Affairs Becton, Dickinson and Company, BD Life Sciences – Integrated Diagnostic Solutions

Phone: 410-316-4984

E-mail: Charles_K_Cooper@bd.com

7 Loveton Circle, Sparks MD 21152, USA

WORD COUNT

1,668 (Introduction, Results, and Discussion); 942 (Methods)

KEY WORDS: SARS-CoV-2; Antigen testing; SARS-CoV-2 contagious; viral load; live

culture; RT-PCR testing

RUNNING TITLE: SARS-CoV-2 antigen testing and infectiousness

¹W. Harry Feinstone Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, ²Department of Emergency Medicine

³Becton, Dickinson and Company, BD Life Sciences – Integrated Diagnostic Solutions, 7 Loveton Circle, Sparks, MD, USA,

⁴Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland

SUMMARY

1

14

will better contain COVID-19.

2 Individuals can test positive for SARS-CoV-2 by real-time polymerase chain reaction (RT-PCR) after no longer being infectious. 1-8 Positive SARS-CoV-2 antigen-based testing exhibits a 3 4 temporal pattern that corresponds with active, replicating virus and could therefore be a more accurate predictor of an individual's potential to transmit SARS-CoV-2. 2,3,9 Using the BD 5 Veritor System for Rapid Detection of SARS-CoV-2 later flow antigen detection test, we 6 7 demonstrate a higher concordance of antigen-positive test results with the presence of cultured, 8 infectious virus when compared to RT-PCR. When compared to infectious virus isolation, the 9 sensitivity of antigen-based testing is similar to RT-PCR. The correlation between SARS-CoV-2 10 antigen and SARS-CoV-2 culture represents a significant advancement in determining the risk 11 for potential transmissibility beyond that which can be achieved by detection of SARS-CoV-2 12 genomic RNA. Coupled with a rapid time-to-result, low cost, and scalability, antigen-based 13 testing should facilitate effective implementation of testing and public health interventions that

INTRODUCTION

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

The SARS-CoV-2 causes COVID-19 and is spread from human-to-human primarily through airborne transmission. ¹⁰ The mean incubation time, or presymptomatic period, for SARS-CoV-2 is approximately 5.8 days (95% CI 5.0-6.7), 11,12 and the period of transmission (the total time during which a patient is contagious) begins around one to three days prior to symptom onset, with a subsequent reduction in contagiousness occurring 7-10 days following symptom onset. 8,13,14 Recent work in a golden hamster SARS-CoV-2 model demonstrated that although the presence of genomic RNA in nasal washes extends to 14 days post-inoculation, the detection of infectious virus and the communicable period both end well before 14 days. ¹⁵ In addition, four previous studies, utilizing culture-based virus detection from human specimens, demonstrated an absence of infectious isolates from most specimens taken eight days after symptom onset, despite measurable viral RNA loads using RT-PCR. 1,3,5,7 Several SARS-CoV-2 antigen-based tests, which work via a lateral flow immunoassay mechanism, have recently received Emergency Use Authorization (EUA) from the Food and Drug Administration. 16-19 Several lines of indirect evidence suggest that antigen-based testing may align better with culture-based test results compared to RT-PCR. For example, higher RT-PCR Ct values from specimens are observed when individuals are negative by antigen testing or culture-based testing compared to those from individual that are antigen test 9 or culture-based test positive. ⁶ In addition, current EUA SARS-CoV-2 antigen tests have optimal performance profiles 16-19 at time points that overlap with the temporal expression profile of SARS-CoV-2 subgenomic RNA (a marker for active, replicating virus).³ Despite the recognition that point-of-care or other testing modalities might be more effective at discerning contagious from non-contagious

served as the reference method for determining infectiousness.

38

39

40

41

42

43

44

45

46

47

48

Pekosz et

individuals, 2 no study has directly compared antigen-based testing with RT-PCR in the same study using a reference method for infectiousness. The objective of this study was to determine whether SARS-CoV-2 antigen testing differentiates SARS-CoV-2-contagious individuals (e.g., those still shedding infectious virus) from noncontagious individuals compared to RT-PCR methodology. To address this, we utilized Quidel Lyra® SARS-CoV-2 Assay ("RT-PCR assay") positive and negative specimens obtained from a diverse set of collection sites across the USA. The RT-PCR assay and the BD VeritorTM System for Rapid Detection of SARS-CoV-2 ("antigen test") were compared to SARS-CoV-2 TMPRSS2 culture (a sensitive virus culture test utilizing the VeroE6TMPRSS2 cell line), which

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

RESULTS The 38 RT-PCR positive specimens were tested for the presence of SARS-CoV-2 using infection of VeroE6TMPRSS2 cell cultures (SARS-CoV-2 TMPRSS2 culture). Overall, 28 RT-PCRpositive specimens were also positive by SARS-CoV-2 TMPRSS2 culture and 10 of 38 RT-PCR-positive specimens were negative by SARS-CoV-2 TMPRSS2 culture (Figure 1A). SARS-CoV-2 TMPRSS2 culture-positive specimens had a mean log10 viral RNA copy number of 7.16 compared to 4.01 from specimens that were SARS-CoV-2 TMPRSS2 culture-negative (p-value <0.001; two-sample t-test, 2-tailed analysis). Further stratification by results from the antigen test showed that 27 of 28 RT-PCR-positive/SARS-CoV-2 TMPRSS2 culture-positive specimens were also positive in the antigen test; only two of the ten RT-PCR-positive/ SARS-CoV-2 TMPRSS2 culture-negative specimens were positive by the antigen test. Of the 38 RT-PCR-positive results utilized for these analyses, nine were antigen test negative. These nine negative results showed a trend towards longer time from symptom onset compared to the 29 RT-PCR assay-positive/antigen test-positive specimens (4.4 days on average versus 2.9, p-value = 0.108). Of the nine samples that were RT-PCR-positive/antigen test-negative, the viral RNA copy number was significantly lower than that observed for the 29 RT-PCRpositive/antigen test-positive specimens (mean 4.3 log10 cp/mL versus 7.0 log10 cp/mL, pvalue<0.001, Figure S1). Symptom day was not a significant factor in multivariate models, while viral RNA load continued to be significant (p-value = 0.002). Probit models for percent positivity by viral RNA load corresponding to the RT-PCR assay,

antigen test, SARS-CoV-2 TMPRSS2 culture, and SARS-CoV-2 culture with VeroE6 cells

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

("SARS-CoV-2 VeroE6 culture;" data integrated into the probit model using previous data; see Methods)⁶ are provided in Figure 1B. The SARS-CoV-2 VeroE6 culture yielded a positive result at a rate of 5% for a viral load of 5.75 log10 cp/ml, whereas the SARS-CoV-2 TMPRSS2 culture corresponded to a positive result with a rate of 5% at a viral load of 4.5 log10 cp/mL. At a viral load of 2.6 log10 cp/mL, the antigen test yielded a positive result at a rate of 5%. In a multivariate generalized linear model with viral RNA load and test type, the SARS-CoV-2 TMPRSS2 culture was not significantly different from the antigen test (p-value = 0.953). Both the SARS-CoV-2 TMPRSS2 culture and antigen test were significantly more likely to yield positive results than SARS-CoV-2 VeroE6 culture (p-value<0.001 for both). Unlike the antigen test, the RT-PCR assay showed very little overlap with SARS-CoV-2 TMPRSS2 culture, yielding positive results at much lower viral loads. As shown in Table 1, the antigen test demonstrated a sensitivity and specificity of 96.4% (95% CI: 82.3, 99.4) and 98.7% (96.1, 99.7), respectively. The RT-PCR assay demonstrated a sensitivity and specificity of 100% (87.7, 100) and 95.5% (91.1, 97.8), respectively. Based on the study prevalence of 11.2%, as determined by SARS-CoV-2 TMPRSS2 culture positivity and a total specimen number of 251 (based on the total, evaluable specimen set utilized for the Veritor EUA study), the positive predictive value (PPV) for the antigen test was 90.0% (76.3, 97.6), while the PPV for the RT-PCR assay was only 73.7% (60.8, 85.3).

92

93

94

95

96

97

98

99

100

101

102

103

104

105

106

107

108

109

110

111

112

DISCUSSION The results here show similar sensitivity between the SARS-CoV-2 antigen test and the SARS-CoV-2 RT-PCR assay (96.4% and 100%, respectively) over a time range of <8 days post symptom onset. However, the SARS-CoV-2 antigen test had a PPV of 90.0%, whereas the RT-PCR assay showed a PPV of only 73.7%. In addition, the probit model for percent positivity employed in this study showed considerable overlap between the antigen test and the SARS-CoV-2 TMPRSS2 culture, with little overlap between the SARS-CoV-2 TMPRSS2 culture and RT-PCR. Ct values are inversely correlated with the viral load thresholds corresponding to infectious virus isolation. Because limits of detection vary between RT-PCR assays, however, Ct values reported by specific RT-PCR assays correspond to different viral RNA loads. 6,7,20-25 Here we utilized the Lyra assay to establish a probit model of percent positivity by viral load, which facilitates a better comparison of these results with previous work. Recent studies involving upper respiratory swab specimens reported no cases of COVID-19 with SARS-CoV-2 viral RNA loads below 4 log10 cp/mL. 1,3,5,6,8,13,26,27 Other work has shown that specimens with viral RNA loads ≤6 log10 cp/ml have minimal or no culturable SARS-CoV-2 virus. 3,5,28-30 Here, a low percent positivity (5-10%) was observed for the SARS-CoV-2 VeroE6- culture test below 6 Log10 cp/mL. The SARS-CoV-2 TMPRSS2 culture test, however, showed 90% positivity at 5.6 log10 cp/mL. Although antigen test had a larger distribution of positivity, it overlapped considerably with the

SARS-CoV-2 TMPRSS2 culture test and approached 90% positivity at a viral RNA load of

6.4Log10. This is consistent with the WHO target product profile for priority diagnostics, which

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

132

133

134

135

supports viral RNA load based methodologies and includes an acceptable limit of detection for point-of-care tests of 6Log10 cp/mL.³¹ As with other viruses, RT-PCR-based methodologies may be detecting SARS-CoV-2 RNA even after infectious virus is no longer present; ³²⁻³⁷ especially at time periods beyond 7 days from symptom onset. 1,3 For most patients with COVID-19, efforts to isolate live virus from upper respiratory tract specimens have been unsuccessful ≥10 days from symptom onset; it is unlikely that these individuals pose a transmission risk to others.²⁵ In addition, there is no evidence to date that persistent or recurrent detection of viral RNA, following recovery from COVID-19, poses a risk of SARS-CoV-2 transmission.²⁵ This work highlights a key potential value of decentralized POC antigen-based testing and furthers our understanding of the interpretation of antigen test results. Antigen testing facilitates accurate and rapid detection of infectious individuals who may not require direct medical management (due to mild/non-severe disease), but for whom infection control measures have the potential to interrupt community transmission. While RT-PCR is highly sensitive when compared to SARS-CoV-2 TMPRSS2culture, antigen testing also showed excellent sensitivity (96.4%) coupled with better PPV relative to RT-PCR (90.0 versus 73.7) and rapid time to results. This study had limitations. It only included specimens from patients within seven days of symptom onset. Several studies have demonstrated an inability to culture SARS-CoV-2 beyond day eight, despite ongoing RT-PCR positivity. 1,3,5 Serial sampling of COVID-19 patients is needed to determine if there is a propensity to have viral antigen test positive results after a

negative result, as can sometimes be seen with RT-PCR tests. Results from this study likely underestimate the difference in specificity between RT-PCR and antigen testing that would be expected in a set that included specimens collected at later times post symptom onset. In this study, while three subjects were antigen test false positives versus SARS-CoV-2 TMPRSS2 culture, as many as ten subjects were RT-PCR false positives versus culture (viral RNA loads ranging from 2.6 to 5.4 log10 copies/mL). Although the sample size was adequate in this study, the confidence intervals in the probit model were too wide to establish a definitive viral load cutoff. To improve the precision associated with the point estimates, either a larger study or a metaanalysis, involving multiple studies, would be required. Also, there are limitations associated with the use of culture positivity or viral RNA load as a surrogate for infectiousness or transmissibility that require further investigation. Finally, it is unclear how well the results here will extrapolate to the other antigen tests due to variability in limit of detection or other test characteristics.

Conclusion

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

154

155

156

157

158

Point-of-care SARS-CoV-2 antigen tests have the potential to significantly change the public health interventions needed to minimize the spread of COVID-19 by providing a better test to identify individuals that are likely to be shedding infectious virus and therefore transmit SARS-CoV-2. This will allow for rapid identification of asymptomatic COVID-19 cases and inform shorter periods of self-isolation for COVID-19 infected individuals. In addition, the low cost and scalability in low and middle-income countries associated with antigen-based testing will be an important tool in the diagnostic armamentarium to contain and suppress COVID-19 community transmission.

160

161

162

163

164

165

166

167

168

169

170

171

172

173

174

175

176

177

178

179

180

181

182

ACKNOWLEDGEMENTS We thank the National Institute of Infectious Diseases, Japan, for providing VeroE6TMPRSS2 cells. We also thank Karen Eckert (Becton, Dickinson and Company, BD Life Sciences – Diagnostic Systems) for her input on the content of this manuscript and editorial assistance and Stanley Chao (Becton, Dickinson and Company, BD Life Sciences – Diagnostic Systems) for statistical support. The individuals acknowledged here have no additional funding or additional compensation to disclose. We are grateful to the study participants who allowed this work to be performed. **AUTHOR CONTRIBUTIONS** All authors contributed to the interpretation of the data, critically revised the manuscript for important intellectual content, approved the final version to be published, and agree to be accountable for all aspects of the work. **FUNDING** This study was funded by Becton, Dickinson and Company; BD Life Sciences—Integrated Diagnostics Solutions. Non-BD employee authors received research funds to support their work for this study. POTENTIAL CONFLICTS OF INTEREST CKC, VP, JCA, SK, JL, DSG, and CR-D are employees of Becton, Dickinson and Company AP—None ML—None YM-None

183	REFI	REFERENCES	
184	1	Bullard, J. et al. Predicting infectious SARS-CoV-2 from diagnostic samples. Clinical	
185		infectious diseases : an official publication of the Infectious Diseases Society of America,	
186		doi:10.1093/cid/ciaa638 (2020).	
187	2	Mina, M. J., Parker, R. & Larremore, D. B. Rethinking Covid-19 Test Sensitivity — A	
188		Strategy for Containment. New England Journal of Medicine,	
189		doi:10.1056/NEJMp2025631 (2020).	
190	3	Wolfel, R. et al. Virological assessment of hospitalized patients with COVID-2019.	
191		Nature 581 , 465-469, doi:10.1038/s41586-020-2196-x (2020).	
192	4	Widders, A., Broom, A. & Broom, J. SARS-CoV-2: The viral shedding vs infectivity	
193		dilemma. Infect Dis Health 25, 210-215, doi:10.1016/j.idh.2020.05.002 (2020).	
194	5	La Scola, B. et al. Viral RNA load as determined by cell culture as a management tool for	
195		discharge of SARS-CoV-2 patients from infectious disease wards. Eur J Clin Microbiol	
196		Infect Dis 39, 1059-1061, doi:10.1007/s10096-020-03913-9 (2020).	
197	6	Huang, C. G. et al. Culture-Based Virus Isolation To Evaluate Potential Infectivity of	
198		Clinical Specimens Tested for COVID-19. <i>J Clin Microbiol</i> 58 , doi:10.1128/JCM.01068-	
199		20 (2020).	
200	7	Gniazdowski, V. et al. Repeat COVID-19 Molecular Testing: Correlation with Recovery	
201		of Infectious Virus, Molecular Assay Cycle Thresholds, and Analytical Sensitivity.	
202		medRxiv, 2020.2008.2005.20168963, doi:10.1101/2020.08.05.20168963 (2020).	
203	8	Arons, M. M. et al. Presymptomatic SARS-CoV-2 Infections and Transmission in a	
204		Skilled Nursing Facility. <i>N Engl J Med</i> 382 , 2081-2090, doi:10.1056/NEJMoa2008457	
205		(2020).	
206	9	Young, S. et al. Clinical evaluation of BD Veritor SARS-CoV-2 point-of-care test	
207		performance compared to PCR-based testing and versus the Sofia 2 SARS Antigen point-	
208		of-care test. Journal of Clinical Microbiology (In press) (2020).	
209	10	Morawska, L. & Cao, J. Airborne transmission of SARS-CoV-2: The world should face	
210		the reality. Environ Int 139, 105730, doi:10.1016/j.envint.2020.105730 (2020).	

211212213	11	McAloon, C. <i>et al.</i> Incubation period of COVID-19: a rapid systematic review and meta- analysis of observational research. <i>BMJ Open</i> 10 , e039652, doi:10.1136/bmjopen-2020- 039652 (2020).
214215216	12	Griffin, J. M. <i>et al.</i> A rapid review of available evidence on the serial interval and generation time of COVID-19. <i>medRxiv</i> , 2020.2005.2008.20095075, doi:10.1101/2020.05.08.20095075 (2020).
217218	13	He, X. <i>et al.</i> Temporal dynamics in viral shedding and transmissibility of COVID-19. <i>Nat Med</i> 26 , 672-675, doi:10.1038/s41591-020-0869-5 (2020).
219220221	14	Byrne, A. W. <i>et al.</i> Inferred duration of infectious period of SARS-CoV-2: rapid scoping review and analysis of available evidence for asymptomatic and symptomatic COVID-19 cases. <i>BMJ Open</i> 10 , e039856, doi:10.1136/bmjopen-2020-039856 (2020).
222223	15	Sia, S. F. <i>et al.</i> Pathogenesis and transmission of SARS-CoV-2 in golden hamsters. <i>Nature</i> 583 , 834-838, doi:10.1038/s41586-020-2342-5 (2020).
224225	16	BinaxNOW TM COVID-19 Ag CARD [package insert, EUA]. Abbott Diagnostics Scarborough, Inc., Scarborough, MA; (2020).
226 227	17	LumiraDx [™] SARS-CoV-2 Ag Test [package insert, EUA]. LumiraDx Group Limited, Dumyat Business Park Alloa FK10 2PB, UK (2020).
228229	18	BD Veritor TM System for Rapid Detection of SARS-CoV-2 [package insert, EUA]. Becton, Dickinson and Company, Sparks-Glencoe, MD; (2020).
230231	19	Sofia® SARS Antigen FIA [package insert, EUA]. Quidel Corporation. San Diego, CA; (2020).
232233234	20	Jacot, D., Greub, G., Jaton, K. & Opota, O. Viral load of SARS-CoV-2 across patients and compared to other respiratory viruses. <i>Microbes Infect</i> , 2020.2007.2015.20154518, doi:10.1016/j.micinf.2020.08.004 (2020).
235236237	21	La Marca, A. <i>et al.</i> Testing for SARS-CoV-2 (COVID-19): a systematic review and clinical guide to molecular and serological in-vitro diagnostic assays. <i>Reprod Biomed Online</i> 41 , 483-499, doi:10.1016/j.rbmo.2020.06.001 (2020).

238239	22	van Kasteren, P. B. <i>et al.</i> Comparison of seven commercial RT-PCR diagnostic kits for COVID-19. <i>J Clin Virol</i> 128 , 104412, doi:10.1016/j.jcv.2020.104412 (2020).
240241242	23	Vogels, C. B. F. <i>et al.</i> Analytical sensitivity and efficiency comparisons of SARS-CoV-2 RT-qPCR primer-probe sets. <i>Nat Microbiol</i> 5 , 1299-1305, doi:10.1038/s41564-020-0761-6 (2020).
243244245	24	Dinnes, J. <i>et al.</i> Rapid, point-of-care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. <i>The Cochrane database of systematic reviews</i> 8 , CD013705, doi:10.1002/14651858.CD013705 (2020).
246247248	25	CDC. Duration of Isolation and Precautions for Adults with COVID-19. Figure 5. Updated September 10, 2020. https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html (Last accessed 9/11/2020).
249250	26	Cevik, M., Bamford, C. G. & Ho, A. COVID-19 pandemic-a focused review for clinicians. <i>Clin Microbiol Infect</i> 26 , 842-847, doi:10.1016/j.cmi.2020.04.023 (2020).
251252	27	Savvides, C. & Siegel, R. Asymptomatic and presymptomatic transmission of SARS-CoV-2: A systematic review. <i>medRxiv</i> , doi:10.1101/2020.06.11.20129072 (2020).
253254	28	Larremore, D. B. <i>et al</i> . Test sensitivity is secondary to frequency and turnaround time for COVID-19 surveillance. <i>medRxiv</i> , doi:10.1101/2020.06.22.20136309 (2020).
255256257	29	Quicke, K. <i>et al.</i> Longitudinal Surveillance for SARS-CoV-2 RNA Among Asymptomatic Staff in Five Colorado Skilled Nursing Facilities: Epidemiologic, Virologic and Sequence Analysis. <i>medRxiv</i> , doi:10.1101/2020.06.08.20125989 (2020).
258259260	30	van Kampen, J. J. A. <i>et al.</i> Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key determinants. <i>medRxiv</i> , 2020.2006.2008.20125310, doi:10.1101/2020.06.08.20125310 (2020).
261262263264	31	WHO. COVID-19 Target product profiles for priority diagnostics to support response to the COVID-19 pandemic v.0.1 Released July 31, https://www.who.int/publications/m/item/covid-19-target-product-profiles-for-priority-diagnostics-to-support-response-to-the-covid-19-pandemic-v.0.1 (2020).

265266267	32	Peiris, J. S. <i>et al.</i> Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. <i>Lancet</i> 361 , 1767-1772, doi:10.1016/s0140-6736(03)13412-5 (2003).
268269	33	Chan, K. H. <i>et al.</i> Detection of SARS coronavirus in patients with suspected SARS. <i>Emerging infectious diseases</i> 10 , 294-299, doi:10.3201/eid1002.030610 (2004).
270271	34	Oh, M. D. <i>et al.</i> Viral Load Kinetics of MERS Coronavirus Infection. <i>N Engl J Med</i> 375 , 1303-1305, doi:10.1056/NEJMc1511695 (2016).
272273274	35	Wang, Y. <i>et al.</i> Factors Associated With Prolonged Viral Shedding in Patients With Avian Influenza A(H7N9) Virus Infection. <i>J Infect Dis</i> 217 , 1708-1717, doi:10.1093/infdis/jiy115 (2018).
275276277	36	Sissoko, D. <i>et al.</i> Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling study. <i>The Lancet. Global health</i> 5 , e80-e88, doi:10.1016/S2214-109X(16)30243-1 (2017).
278279	37	Paz-Bailey, G. <i>et al.</i> Persistence of Zika Virus in Body Fluids - Final Report. <i>N Engl J Med</i> 379 , 1234-1243, doi:10.1056/NEJMoa1613108 (2018).
280 281 282	38	Meng, X., Deng, Y., Dai, Z. & Meng, Z. COVID-19 and anosmia: A review based on upto-date knowledge. <i>American journal of otolaryngology</i> 41 , 102581, doi:10.1016/j.amjoto.2020.102581 (2020).
283 284 285	39	Fu, L. <i>et al.</i> Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: A systematic review and meta-analysis. <i>J Infect</i> 80 , 656-665, doi:10.1016/j.jinf.2020.03.041 (2020).
286 287 288	40	Bossuyt, P. M. <i>et al.</i> STARD 2015: An Updated List of Essential Items for Reporting Diagnostic Accuracy Studies. <i>Radiology</i> 277 , 826-832, doi:10.1148/radiol.2015151516 (2015).
289 290	41	Lyra® SARS-CoV-2 Assay [package insert, EUA]. Quidel Corporation. Athens, OH; (2020).
291 292	42	Matsuyama, S. <i>et al.</i> Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. <i>Proc Natl Acad Sci U S A</i> 117 , 7001-7003, doi:10.1073/pnas.2002589117 (2020).

Pekosz et

293	43	Waggoner, J. J. et al. Triplex Real-Time RT-PCR for Severe Acute Respiratory
294		Syndrome Coronavirus 2. Emerging infectious diseases 26, 1633-1635,
295		doi:10.3201/eid2607.201285 (2020).
296	44	Wickham, H. ggplot2: Elegant Graphics for Data Analysis. Springer-Verlag New York,
297		(2016).
298	45	R Core Team . R: A language and environment for statistical computing. R Foundation
299		for Statistical Computing, Vienna, Austria. https://www.R-project.org/ (2020).

METHODS

300

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

Study design and specimen collection Prospective specimen collection, specimen use, and participant demographics for the parent study were described previously. This study involved the use of residual respiratory swab specimens from the previous antigen test Food and Drug Administration-Emergency Use Authorization (EUA) study, which occurred across 21 geographically diverse study sites, from June 5-11, 2020. Briefly, eligible participants were ≥18 years of age and had one or more selfreported COVID-19 symptoms between 0-7 days from symptom onset. 38,39 Nasal swab specimens for use with antigen testing were collected only after the standard of care (SOC) swab. Nasopharyngeal (NP) swab specimens were collected after the nasal swab specimen for use with the RT-PCR assay (the laboratory reference standard in the EUA study); if an NP was collected as part of the SOC procedure at a collection site, the participant was given the choice of having an oropharyngeal (OP) swab specimen collected in lieu of a second NP swab for use with the RT-PCR assay. Overall, 76 specimen sets (consisting of one nasal and either one NP or one OP swab) were utilized from the original 251 evaluable specimen sets in the EUA study. The 76 specimens consisted of all 38 RT-PCR assay positive specimens, and 38, randomly selected RT-PCR assay negative specimens from the parent study. Specimens for the RT-PCR assay consisted of 71 NP swabs (37 and 34 positive and negative, respectively) and five OP swabs (1 and 4 positive and negative swabs, respectively). For the EUA study, reference testing was performed at TriCore Reference Laboratories while the antigen testing was performed internally at BD (San Diego, CA, USA). No study-related procedures were performed without an informed consent process or signature of a consent form. This research was performed in alignment with

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

principles set forth by Good Clinical Practice guidelines and the-Declaration of Helsinki. This article was prepared according to STARD guidelines for diagnostic accuracy studies reporting.⁴⁰ *Test/assay procedures* Antigen test and RT-PCR assay The antigen test (Becton, Dickinson and Company, BD Life Sciences—Integrated Diagnostic Solutions, San Diego, CA) and RT-PCR assay (Quidel Corporation. Athens, OH) were performed according to the manufacturers' IFU. 19,41 The only exception was that nasal swabs were shipped on dry ice (-70°) to the testing site prior to preparation for the antigen test. The RT-PCR assay reports cycle number in a manner that omits the first 10 cycles; here cycle numbers for the RT-PCR assay are reported with the addition of first 10 cycles. SARS-CoV-2 virus culture VeroE6TMPRSS2 was adapted from the VeroE6 cell line (ATCC CRL-1586) to express the TMPRSS2 protease at levels approximately 10-fold higher than that found in the human lung.⁴² The cells were cultured in complete medium (CM) consisting of Dulbecco's modified Eagle Medium, supplemented with 10% fetal bovine serum (Thermo Fisher Scientific-Gibco, Waltham, MA), 1mM glutamine (Thermo Fisher Scientific-Invitrogen, Waltham, MA), 1mM sodium pyruvate (Thermo Fisher Scientific-Invitrogen, Waltham, MA), 100µg/mL penicillin (Thermo Fisher Scientific-Invitrogen, Waltham, MA) and 100 µg/mL streptomycin (Thermo Fisher Scientific-Invitrogen, Waltham, MA), at 37°C in a humidified chamber with 5% carbon dioxide. Cells were grown to 75% confluence in a 24 well plate format and the CM was removed and replaced with 150 µL of infection media (IM) which is identical to CM but with the fetal

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

bovine serum reduced to 2.5%. One hundred microliters (100 µL) of the clinical specimen was added to each assay well and the cells were incubated at 37°C for two hours. The inoculum was then aspirated and replaced with 0.5 ml IM; the cells were then maintained at 37°C for four days. When a cytopathic effect was visible in most of the cells in a given well, the IM was harvested and stored at -70°C. The presence of SARS-CoV-2 was confirmed through quantitative RT-PCR as described previously, ^{7,43} by extracting RNA from the cell culture supernatant using the Oiagen viral RNA isolation kit and performing RT-PCR using the N1 and N2 SARS-CoV-2 specific primers and probes in addition to primers and probes for human RNaseP gene using synthetic RNA target sequences to establish a standard curve. Probit models for probability of positive SARS-CoV-2 result The RT-PCR assay was performed on serially diluted samples containing SARS-CoV-2 related genomic RNA prepared in universal transport media (containing human lung epithelial cells at 130,000 cells per mL) at concentrations ranging from 1.27 log10 copies/mL (cp/ml) to 4.27 log10 cp/ml (Table S1). The RT-PCR assay probability of positive result was fit using a probit model linking the Lyra results to viral RNA load. Linear regression was performed linking log10 cp/ml viral RNA load to Lyra Ct score using all samples with at least 3 log10 cp/ml (for which observed Lyra positivity was 100%). Antigen test positivity and SARS-CoV-2 TMPRSS2 culture positivity (a surrogate for contagiousness), with RT-PCR confirmation, were fit with a probit model as a function of viral load, using results from the Veritor EUA study; RT-PCR assay Ct scores were used to estimate viral RNA loads, as described above. SARS-CoV-2 VeroE6 culture positivity linkage to viral

369

370

371

372

373

374

375

load was inserted into the probit model for probability of a positive result using data from Huang et al (2020). Virus isolation in Huang et al was attempted for a total of 60 specimens, positive by RT-PCR for SARS-CoV-2. Of those, 23 were positive by culture. Ct scores of the SARS-CoV-2 envelope, nucleocapsid, and non-structural protein-12 RT-PCR targets were linked to the viral load (log10 cp/ml) through quadratic regressions. The empirical equation for envelope target Ct score was then used to calculate viral load for the 23 culture positive and 37 culture negative specimens (Figure S2). All analyses were performed using the R software system and the ggplot2 R package. 44,45




Table 1. Performance of the antigen test and the RT-PCR assay for detection of SARS-CoV-2 infectivity based on virus culture positive results within 0-7 days from symptom onset


Prevalence: 11.2%			
Performance values	Antigen test performance	RT-PCR assay performance	
Sensitivity	96.4 [82.3, 99.4]	100 [87.7, 100]	
Specificity	98.7 [96.1 99.7]	95.5 [91.1, 97.8]	
PPV	90.0 [76.3, 97.6]	73.7 [60.8, 85.3]	
NPV	99.5 [97.7, 100]	100 [98.4, 100]	
Accuracy	98.4 [96.0, 99.4]	96.0 [92.8, 97.8]	
TP	27	28	
FP	3	10	
FN	1	0	
TN ^a	220	213	

Abbreviations: RT-PCR, real-time polymerase chain reaction; PPV, positive predictive value; NPV, negative predictive value; TP, true positive; FP, false positive; FN, false negative; TN, true negative

^aincludes 176 specimen sets that were RT-PCR and antigen negative, with unavailable culture results.










Figure 1. (A) The 38 RT-PCR assay positive specimens are plotted by Log10 copies/mL (y-axis) and are stratified by the SARS-CoV-2 live culture results (negative, n=10; positive, n=28). The median and inter-quartile range values, respectively, for the RT-PCR-positive/SARS-CoV-2 TMPRSS2 culture-negative were 4.21 and 1.37; the median and inter-quartile range values, respectively, for the RT-PCR-positive/SARS-CoV-2 TMPRSS2 culturenegative were 7.39 and 1.66. The mean values for the SARS-CoV-2 TMPRSS2 culture-negative and SARS-CoV-2 TMPRSS2 assay-positive specimen groups were significantly different (4.01 versus 7.16, respectively; p-value <0.001 based on two-sample t-test [2-tailed]). Antigen test positive results are indicated as red data points (n=29) and the antigen test negative results (n=9) are indicated by the green data points. (B) Probit models linking viral load to the probability of positive result of RT-PCR (Lyra), antigen test (Veritor), SARS-CoV-2 TMPRSS2 culture and SARS-CoV-2 VeroE6 culture (refer to Huang et al 2020). Viral load levels at which there is a 5% chance of positive result: 1.6, 2.6, 4.5, and 5.75 log10 cp/ml for RT-PCR, antigen, SARS-CoV-2 TMPRSS2 culture, and SARS-CoV-2 VEroE6 culture, respectively.

SUPPLEMENTAL MATERIAL TABLE S1

Table S1. Corresponding values for Ct score and viral RNA load during limit of detection analysis involving Lyra SARS-CoV-2 RT-PCR assay-positive specimens

Viral Load	Log10	#Positive/	PCR assay
(copies/mL)	Viral Load	#Tested	Ct score; Mean (SD)
0	=	0/5	- (-)
19	1.27	0/9	- (-)
40	1.60	1/10	38.03 (-)
86	1.94	1/9	38.83 (-)
186	2.27	4/10	37.33 (1.20)
400	2.60	8/10	35.89 (1.69)
862	2.94	8/10	34.51 (1.62)
1857	3.27	10/10	32.66 (1.07)
4000	3.60	10/10	31.08 (0.75)
8618	3.94	9/9	30.09 (1.15)
18566	4.27	9/9	29.51 (1.45)

479

480

481

482





Figure S1. Box plots showing the median values for SARS-CoV-2 viral RNA loads from antigen-positive and -negative results within the 38 RT-PCR-positive results from the Veritor test EUA study. A two-sample t-test (2-tailed) analysis indicated a significantly higher mean (7.0 log10 cp/ml) for RT-PCR-positive/antigen-positive results compared to






FIGURE S2

483

484 485

486

487

488

489 490

Figure S2. Relation of the RT-PCR Ct scores for the BD MAX assay, the RT-PCR assay, and the RT-PCR method used in Huang et al (2020)⁶ to viral load. Empirical equation for the RT-PCR assay Ct = 42.69 - 3.14 Log10 copies/mL. Empirical equation for the E target in Huang et al: Log10 copies/mL = 12.377 - 0.052 Ct - 0.005 Ct²